Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma

BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:ERJ Open Res
Asıl Yazarlar: Castro, Mario, Rabe, Klaus F., Corren, Jonathan, Pavord, Ian D., Katelaris, Constance H., Tohda, Yuji, Zhang, Bingzhi, Rice, Megan S., Maroni, Jaman, Rowe, Paul, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Akinlade, Bolanle, Graham, Neil M.H., Teper, Ariel
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: European Respiratory Society 2020
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6983496/
https://ncbi.nlm.nih.gov/pubmed/32010719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00204-2019
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller